Home / Resources / Late Clinical resources

晚期临床

精选资源

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

公告

Upcoming late clinical webinars

网络研讨会

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

2026 年 4 月 28 日 – 10:00-11:00am

网络研讨会

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Apr 29, May 1

网络研讨会

Pharmacometrics Under Pressure

Apr 30, May 6, May 15 – 10:00 - 11:00am ET

Latest late clinical blogs

All Late clinical - blog

Blog

生物模拟和人工智能技术如何解决制药业的研发生产力危机

在以下活动中与我们的专家会面

现场活动

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

2026 年 5 月 7 日 – San Diego, CA

会议

ISPOR International Annual Conference 2026

May 17 - 20, 2026 – Philadelphia, PA

会议

CDISC EU 2026

May 18 - 22, 2026 – Milan, Italy

All late clinical resources

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Modeling and Simulation - PK/PD, Blog, Knowledge Base

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

ADC, Certara Services, Clinical Pharmacology, Drug Development, Modeling and Simulation, On-Demand Webinar

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Pharmacometrics, Therapeutic Specialties, Case Study

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Certara Products, Certara Products - Phoenix, Certara Products - Simcyp, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Certara Products - Pinnacle 21, Blog

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Webinar

How Bayesian Design Is Reshaping Clinical Development

Certara Services, Press Coverage, Video

Where Did the 80-125% Bioequivalence Criteria Come From?

Modeling and Simulation - PK/PD, Blog, Knowledge Base

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Biologics, Cardiovascular, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Publication

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

ADC, Biologics, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, On-Demand Webinar

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - QSP, Blog

1
2
3
……
47
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

晚期临床

最新资源

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

精选资源

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Upcoming late clinical webinars

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Pharmacometrics Under Pressure

Latest late clinical blogs

回顾创纪录的 2025 Krakow HTA Symposium

药物开发中 PK/PD 建模的机器学习

为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大

2024 年 Pinnacle 21 Enterprise 用户会议上聚焦临床研究软件

Don’t Miss Our Inaugural Event for Biosimulation Users

生物模拟和人工智能技术如何解决制药业的研发生产力危机

在以下活动中与我们的专家会面

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

ISPOR International Annual Conference 2026

CDISC EU 2026

All late clinical resources

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Data Fabrics in Pharma: Connecting Data for Better Decisions

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

How Bayesian Design Is Reshaping Clinical Development

Where Did the 80-125% Bioequivalence Criteria Come From?

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

订阅时事通讯

快捷链接

解决方案

联系我们